Drug Delivery Device for Age-Related Macular Degeneration (AMD)
Karl G. Csaky, M.D., Ph.D., Director, Molecular Ophthalmology Laboratory, is working with his research team to develop a drug delivery device for patients with age-related macular degeneration (AMD). It is a small Polymer device that slowly releases therapeutic drugs as needed over a period of weeks, months or years as prescribed by your physician. The device is placed on the outer part of the eye and does not interfere with patient vision or comfort. The device can remain in place for a long period of time as prescribed by the physician care team. Placement of the implant on the surface of the eye, rather than inside the eye, allows for long-term drug delivery to the eye. This innovative drug delivery device allows physicians to administer medication delivery in a less invasive way, and better manage the disease.
Related ArticlesRetina Foundation Announces 2023 Visionary Luncheon and Sets $1 Million Fundraising Goal Gene Causing Blindness Found in Texas Hispanic Families New iPad Amblyopia Treatment is a “Hot Topic” Retina Foundation CEO Shares Fundraising Goals to Preserve and Save Vision Promising Results From Ongoing Phase 1/2 Clinical Trial for X-Linked Retinitis Pigmentosa (XLRP)